Answers are grounded in this paper and cite their sources.
Clinical commentary reveals risks of NSAID-induced nephrotoxicity in horses with acute kidney injury, emphasizing opioid analgesia and questioning selective COX-2 safety advantages.
This clinical commentary accompanies the case report from Quinn et al. (2026) on the successful anaesthetic management of a horse with traumatic injuries that subsequently developed acute kidney injury (AKI).During the acute phase, analgesia was managed without the use of nonsteroid anti-inflammatory drugs (NSAIDs), instead relying on systemic and epidural opioid administration in consideration of the concurrent renal impairment.However, following the normalisation of serum creatinine concentrations (sCr), the filly was treated with phenylbutazone (PBZ), followed by flunixin, despite the persistence of mild isosthenuria and marked polyuria.These clinical decisions highlight the complexity of balancing effective analgesia with ongoing concerns regarding renal recovery and/or causing additional nephrotoxicity.Overall, the report reinforces the importance of minimising NSAID use in horses with AKI whenever feasible, with opioids representing a valuable alternative.The report suggests no clear renal advantage of cyclo-oxygenase (COX)-2 preferential/selective NSAIDs over nonselective NSAIDs.The aim of this clinical commentary is to provide an overview of the current understanding of NSAID-associated nephrotoxicity, with the goal of supporting informed clinical decision-making regarding NSAIDs use in horses.
No takes yet. Share an insight, caveat, or question.
Donato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: